Ubs Group Ag Novo Cure LTD Put Options Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	SELL	$11.83 - $24.05 $127,764 - $259,740	-10,800 Reduced 98.18%	200 $3,000
Q1 2024 May 13, 2024	SELL	$12.42 - $17.29 $1.65 Million - $2.3 Million	-132,900 Reduced 92.36%	11,000 $171,000
Q3 2023 Nov 09, 2023	BUY	$16.15 - $42.35 $931,854 - $2.44 Million	57,700 Added 66.94%	143,900 $2.32 Million
Q2 2023 Aug 11, 2023	BUY	$40.29 - $82.51 $3.09 Million - $6.32 Million	76,600 Added 797.92%	86,200 $3.58 Million
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $22,576 - $47,524	400 Added 4.35%	9,600 $577,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $4.74 Million - $7.94 Million	-40,800 Reduced 81.6%	9,200 $1.07 Million
Q2 2021 Aug 13, 2021	BUY	$130.4 - $225.58 $4.36 Million - $7.53 Million	33,400 Added 201.2%	50,000 $11.1 Million
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $291,616 - $452,763	2,600 Added 18.57%	16,600 $2.87 Million
Q1 2020 May 01, 2020	SELL	$57.05 - $95.75 $690,305 - $1.16 Million	-12,100 Reduced 46.36%	14,000 $943,000
Q4 2019 Feb 14, 2020	BUY	$68.3 - $93.8 $956,200 - $1.31 Million	14,000 Added 115.7%	26,100 $2.2 Million
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $748,506 - $1.18 Million	12,100 New	12,100 $905,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.16B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.